Understand the source comparison
How to Use KPV for Antimicrobial Protocol: Research Model Comparison
Rodent colitis (DSS, TNBS) 1–3mg/kg Intraperitoneal or subcutaneous 1 hour pre-challenge or concurrent 60–80% reduction in IL-6, TNF-alpha, IL-1beta at peak inflammation (day 5–7) Gold standard for inflammatory bowel research. Results translate well to epithel
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Rodent colitis (DSS, TNBS)
- 1–3mg/kg
- Intraperitoneal or subcutaneous
- 1 hour pre-challenge or concurrent
- 60–80% reduction in IL-6, TNF-alpha, IL-1beta at peak inflammation (day 5–7)
- Gold standard for inflammatory bowel research. Results translate well to epithelial barrier models
- Chronic wound biofilm
- 0.5–1mg per wound site
- Local subcutaneous injection around wound margin
- Daily for 7–14 days starting at wound creation
- 40–60% reduction in neutrophil infiltration, no direct effect on bacterial CFU unless combined with antibiotics
- Effective for reducing inflammation-driven biofilm persistence, not a standalone antimicrobial
- Cell culture (macrophages, epithelial)
- 10–100μM
- Direct addition to culture medium
- 30 min pre-stimulation with LPS or cytokines
- 50–70% reduction in NF-κB-driven cytokine secretion (ELISA-confirmed)
- Best for mechanistic studies. Allows dose-response curves and pathway validation
- Respiratory infection (bacterial pneumonia)
- 2–3mg/kg
- Intranasal or intraperitoneal
- Concurrent with bacterial challenge, repeat at 12h and 24h
- 30–50% reduction in lung IL-6 and neutrophil count, modest improvement in bacterial clearance when combined with antibiotics
- Promising but understudied. Works best when inflammation, not bacterial load, is the primary pathology driver
- The bottom line: KPV performs best in models where inflammation sustains pathogen persistence. Not acute infections where bacterial load is the sole determinant of outcome. If your model shows no improvement in bacterial CFU with KPV alone, that's expected. The peptide's role is reducing the inflammatory damage that allows chronic infection to establish.